Vasodilator responsiveness in idiopathic pulmonary arterial hypertension: identifying a distinct phenotype with distinct physiology and distinct prognosis

Abstract

Within the cohort of patients suffering from idiopathic pulmonary arterial hypertension (IPAH) is a group that responds dramatically (VR-PAH) to an acute vasodilator challenge and that has excellent long-term hemodynamic improvement and prognosis on high dose calcium channel blockers compared with vasodilator non-responders (VN-PAH). For the purposes of diagnosing VR-PAH, there is to date no test to replace the acute vasodilator challenge. However, recent studies have identified markers that may aid in the identification of VR-PAH, including peripheral blood lymphocyte RNA expression levels of desmogelin-2 and Ras homolog gene family member Q, and plasma levels of provirus integration site for Moloney murine leukemia virus. Genome wide-array studies of peripheral blood DNA have demonstrated differences in disease specific genetic variants between VR-PAH and NR-PAH, with particular convergence on cytoskeletal function pathways and Wnt signaling pathways. These studies offer hope for future non-invasive identification of VR-PAH, and insights into pathogenesis that may lead to novel therapies. Examination of the degree of pulmonary microvascular perfusion in PAH has offered additional insights. During the acute vasodilator challenge, VR-PAH patients demonstrate true vasodilation with recruitment and increased perfusion of the capillary bed, while VN-PAH patients are unable to recruit vasculature. In the very few reports of lung histology, VR-PAH has more medial thickening in the precapillary arterioles, while VN-PAH has the classic histology of PAH, including intimal thickening. VR-PAH is a disorder with a phenotype distinct from VN-PAH and other types of PAH, and should be considered separately in the classification of PAH.

Keywords

pulmonary arterial hypertension vasodilator responsiveness calcium channel blocker microvasculature pulmonary capillary surface area pulmonary vascular imaging

Introduction

From many aspects, idiopathic PAH (IPAH) remains an enigma. In most patients, pulmonary microvascular cell proliferation and abnormalities of endothelial mediator production result in precapillary vascular luminal restriction, increased pulmonary vascular resistance (PVR), and a loss of perfused downstream pulmonary capillary surface area.^1,2 The underlying causes and pathogenic mechanisms are not fully elucidated. The diagnosis of IPAH is based on having a mean pulmonary arterial pressure (mPAP) ≥ 25 mm Hg, pulmonary artery wedge pressure (PAWP) ≤ 15 mmHg, and PVR > 3 Wood units, after exclusion of other causes of pulmonary hypertension.³ Recent identification of associated gene mutations allows for very specific diagnosis in some patients.⁴

Within the cohort of IPAH patients is a group of otherwise clinically indistinguishable subjects that behave differently during an acute vasodilator challenge. Unlike the rest, this minority of IPAH patients demonstrates a marked vasodilator response, has a sustained response to high-dose oral calcium blocker therapy, and has a seemingly superb long-term outcome and survival.^5–7 Recent physiologic and molecular studies suggest that this group with vasodilator-responsive PAH (VR-PAH) represents a distinct phenotype within the IPAH population.^8–10

History

The description of primary pulmonary hypertension (PPH, now termed IPAH) and its hemodynamic analysis led to the observation that some patients responded acutely to pulmonary vasodilators.^11–13 Many systemic antihypertensive agents were subsequently tested during acute vasodilator challenges and as chronic therapy, including hydralazine, phentolamine, captopril, diazoxide, isoproterenol, conventional-dose nifedipine, tolazoline, and others.^14–26 They were abandoned when it became evident that they generally had little long-term beneficial effect on pulmonary hemodynamics in IPAH patients but had adverse effects including lowering systemic blood pressure, sometimes to dangerous levels.^27–36 Moreover, they did not provide criteria for predicting a chronic vasoresponder group.³⁷ Although the possibility of a response was not linked to the severity of PVR elevation, there was a suggestion that participants with a less abnormal resting PVR had a greater likelihood of responding³⁷ (Fig. 1).

Fig. 1.

Frequency distribution of patients with primary pulmonary hypertension (PPH, now termed IPAH) in a review of prior publications, ranked by PVR (Wood units). The dark areas represent the number of patients that demonstrated some degree of vasoresponsiveness during an acute vasodilator challenge. Reproduced with permission of the American Thoracic Society, from Reeves et al.³⁷ Copyright © 2017 American Thoracic Society. The American Review of Respiratory Disease is an official journal of the American Thoracic Society.

There are several possibilities for these failures. First, a given medication may simply have been ineffective. Second, the medication might have been somewhat effective, but only in a minority of patients, and the evidence of benefit was obscured within a group that contained a large number of vasodilator non-responsive (VN-PAH) patients. Third, the criteria for response may have been incorrect. Many of the studies were able to demonstrate an increase in cardiac output with at times very significant reductions in calculated PVR, but without any decrease in pulmonary artery pressure.^15,18 This was termed a “resistance” response, as opposed to a “pressure” response which consists of a true fall in PAP with either an increase or no change in cardiac output, also resulting in a decrease in calculated PVR. As discussed below, these two patterns of response have very different physiologic implications in terms of distention and recruitment of pulmonary microvasculature. A careful analysis of multiple studies suggested that using a “resistance” response as an indicator of therapeutic benefit was insufficient and misleading and, by current criteria, the participants would be considered as VN-PAH patients.³⁸

The need for safer and effective agents for acute vasodilator testing led to the study of prostanoids, inhaled nitric oxide, and adenosine.^39–49 All have a short duration of action, none impair myocardial contractility, and inhaled nitric oxide has no systemic vasodilator effects. Adenosine is given intravenously, while the prostanoids may be given intravenously or via inhalation. While not identical, the vasodilator response to one type of agent correlates with the others.^39,40,42,47 Guidelines for use of these agents as acute vasodilators have recently been updated.⁵⁰ Inhaled nitric oxide at 20 parts per million (ppm) is the preferred testing agent, although some studies have used increments up to 80 ppm. Intravenous epoprostenol is started at 2 ng/kg/min, with increments of 2 ng/kg/min every 10 min up to a maximum of 16 ng/kg/min, watching for effectiveness, or side effects including systemic hypotension. Adenosine infusions are started at 0.001 mg/kg/min, with increments of 0.01–0.02 mg/kg/min every 10 min, up to a maximum dose of 0.05 mg/kg/min.

In 1987, Rich and Brundage described 13 patients with PPH that were challenged with hourly oral doses of the calcium channel blockers nifedipine or diltiazem until they experienced adverse effects or until they demonstrated a positive response defined as a minimum 50% reduction in PVR and a minimum 33% decrease in mPAP.⁵ The participants had essentially no response to a single conventional dose of the calcium blockers. However, after hourly dosing, eight patients (62%) met the response criteria defined above. Five patients had hemodynamic follow-up at one year, with sustained benefit in four of them, on daily doses of calcium channel blockers as high as 180 mg of nifedipine or 720 mg of diltiazem. Another responder died after reducing her nifedipine dose to 40 mg/day. In a subsequent study of 64 patients, using a criterion of a minimum 20% decrease in both PAP and PVR, 17 (27%) were responders.⁶ Thirteen of the 17 had sustained hemodynamic benefit in long-term follow-up, in some cases up to five years (Fig. 2). The survival of the responders was 94% at five years compared with a predicted three-year survival of 55%. Another report of 47 patients using the same criteria described a response rate of 32%.⁵¹ The importance of a “pressure” response versus a “resistance” response was emphasized.

Fig. 2.

Effects of high-dose calcium blocker therapy in a group of VR-PAH patients, showing effects up to a five-year period in: pulmonary artery pressure (left); PVR (Wood units, center), and survival (right). Reproduced with permission from Massachusetts Medical Society, from Rich et al.⁶ Copyright © 2017 Massachusetts Medical Society.

In 2005, Sitbon et al. described 557 IPAH patients that had undergone vasodilator testing with intravenous epoprostenol or inhaled nitric oxide.⁷ They employed the traditional criteria of a minimum 20% decrease in mPAP and in PVR. They defined a long-term calcium channel blocker response as the patients being in World Health Organization (WHO) functional class I or II at one year. Seventy patients (12.5%) met the criteria for acute vasoresponsiveness. However, only 38 (6.8%) had long-term improvement on calcium channel blockers. In those patients, the average seven-year survival was 97%, and they had less severe hemodynamic abnormalities at baseline than the patients who failed calcium blockers. The study led to a reconsideration of the definition of a vasodilator responder. Based on the data, an acute response is now defined as a decrease in mPAP ≥ 10 mmHg to a mPAP of ≤ 40 mmHg, with an unchanged or increased cardiac output.⁵⁰ PVR was not a predictor of long-term response. Another study explored the relationship between acute vasodilator responsiveness and long-term calcium blocker responsiveness in patients with PAH other than idiopathic.⁵² With the exception of PAH related to anorexigens, the incidence of acute responsiveness was either low or did not predict a long-term response, and the incidence of long-term responses was very low (Fig. 3). The current guidelines suggest acute vasodilator testing and long-term use of calcium channel blockers only in patients with IPAH, heritable PAH, and drug-induced PAH.⁵⁰

Fig. 3.

Percentage of PAH patients responding to an acute vasodilator challenge and to long-term calcium channel blocker (CCB) therapy, ranked by the condition associated with the PAH (on the vertical axis). Only PAH associated with appetite suppressants has a long-term response to CCB. Reproduced with permission from the European Society of Cardiology and Oxford University Press, from Montani et al.⁵²

Calcium channel blockers should not be used as acute vasodilator testing agents as they may have acute systemic vasodilator and negative inotropic effects, resulting in decreased cardiac output or hypotension, and they have a long duration of action should deleterious effects occur.

Blood and genetic markers, and histology, of vasoreactivity and long-term response

Other than with the acute vasodilator challenge, which is invasive and costly, there are currently no simple methods that can identify VR-PAH patients. However, recent studies are beginning to provide a molecular basis for the distinct behavior of VR-PAH patients and offer the hope for a simple screening tool and for understanding the cause(s) of VR-PAH. Hemnes et al. studied cultured peripheral blood lymphocytes from IPAH patients and, based on gene expression RNA patterns, formed a decision tree that correctly identified VR-PAH patients.⁹ The trees were then validated using an IPAH cohort from a second PH specialty center (Fig. 4). While there were significant differences in expression in 13 genes, the expression levels of two genes proved central and sufficient to the development of the decision tree: DSG2 and RHOQ. Desmoglein-2 (DSG2) is a desmosomal cadherin that affects Wnt/β-catenin signaling, cell–cell adhesion, and calcium binding. Abnormal Wnt/β-catenin signaling may contribute to the pathogenesis of IPAH.^53–55 Mutations in DSG2 have been described in arrhythmogenic right ventricular cardiomyopathy (ARVC).^56–59 Interestingly, a mutation in a gene coding for phospholamban has also been described in ARVC.⁶⁰ Phospholamban regulates the sarcoplasmic reticulum calcium load and it has been proposed that this may result in maladaptive remodeling of the intercalated disk. This finding of altered cellular calcium handling may be relevant to VR-PAH, given the necessary unconventionally high calcium channel blocker doses required to maintain therapeutic benefit. Ras homolog gene family, member Q (RHOQ), is a cytoskeletal GTPase involved in protein transport and insulin-mediated signaling.^61,62 Abnormalities in glucose handling have been described in PAH.^63,64 Taken together, when expression levels relative to hypoxanthine guanine phosphoribosyl tranferase expression were measured by PCR, a RHOQ level ≥ 2.8 and a DSG2 level ≥ −7.8 as primary genes, with TPD52 ≥ −0.39 as a secondary gene, correctly identified VR-PAH, with no false positives or negatives. This technique represents a significant advance in detecting VR-PAH using a peripheral blood sample.

Fig. 4.

An example of a screening strategy to distinguish VR-PAH from NR-PAH, based on gene expression patterns in RNA from peripheral blood lymphocytes. Measurements of relative expression of desmoglein-2 (DSG2) and Ras homolog gene family member Q (RHOQ), compared with expression of hypoxanthine guanine phosphoribosyl transferase, correctly identified VR-PAH, with no false positives or negatives. Reproduced with permission from Hemnes et al.⁹

In another approach, Renard et al. demonstrated that plasma levels of provirus integration site for Moloney murine leukemia virus (Pim-1) could differentiate VR-PAH from NR-PAH⁶⁵ (Fig. 5). Pim-1 is a proto-oncogene that activates the NFAT/STAT3 pathway and may contribute to the pathogenesis of PAH, at least in its proliferative form.⁶⁶ Participants with VR-PAH had levels of Pim-1 similar to those of healthy volunteers. By contrast, patients with NR-PAH and PAH from connective tissue disease had higher levels of Pim-1. The predictive threshold for distinguishing NR-PAH from VR-PAH was >8.2 ng/mL, with a sensitivity of 79% and a specificity of 100%. These results are intriguing because they may allow for separation of VR-PAH from VN-PAH via a peripheral blood test. It is unknown whether combining the above approaches of Hemnes and Renard would provide even greater discriminatory power.

Fig. 5.

Plasma levels of provirus integration site for Moloney murine leukemia virus (Pim-1) in healthy volunteers (HV), connective tissue disease (CTD) without or with PAH, PAH associated with congenital heart disease (CHD-PAH), and idiopathic PAH which was vasoresponsive (VR-IPAH) or non-responsive (NR-PAH). Pim-1 levels in VR-IPAH are similar to those of healthy volunteers. Reproduced with permission from Renard et al.⁶⁵

Examination of genetic variants may also help. Using peripheral blood-derived DNA, Hemnes et al. analyzed IPAH patients (17 VR-PAH, 19 VN-PAH) and identified 1580 genetic variants that were specific to the disease.¹⁰ With whole exome sequencing, they found that the variants converged on cytoskeletal function pathways and the Wnt signaling pathway (Fig. 6). Compared with VN-PAH, vascular smooth muscle contraction-related genes were enriched in VR-PAH. The authors suggest that, if there is a shared gene regulating smooth muscle contraction, this may explain why vasodilators with different mechanisms of action (i.e. prostanoids, nitric oxide, adenosine, and calcium blockers) are effective in VR-PAH. Moreover, since the number of variants was higher in VR-PAH than VN-PAH, VR-PAH might have a completely genetic disposition or VR-PAH might result from pathways related to VN-PAH being further modified. It is currently unknown which possibility is correct. All the above studies identify markers for VR-PAH versus NR-PAH, but they also offer mechanistic insights that may ultimately lead to better therapies.

Fig. 6.

Examination of genetic variants in peripheral blood-derived DNA from VR-PAH and VN-PAH patients. This figure focuses on the Wnt signaling pathway. Note the differing frequency of gene mutations as well as the differences in novel gene variants between VR-PAH and NR-PAH. Reproduced with permission of the American Thoracic Society, from Hemnes et al.¹⁰ Copyright © The American Thoracic Society. The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.

There have been no recent descriptions of pulmonary vascular histology in responders to an acute vasodilator challenge or in long-term calcium blocker responders. These patients have a lengthy survival and have not presented to autopsy. Given the rapid dramatic reduction in vascular resistance during acute vasodilator challenge in responders, one hypothesis is that the problem resides in the precapillary arteriolar smooth muscle cell layer and results nearly exclusively from vasoconstriction, and that the intimal cellular proliferation seen in many patients with IPAH must not be predominant. In support of this, the lung tissue from a ten-year-old boy with IPAH and significant acute vasodilator responsiveness showed only medial hypertrophy and minimal intimal thickening in the pulmonary arteries.⁶⁷ Moreover, in the only morphometric study of lung biopsy tissue from VR-PAH, defined as a >30% decrease in PVR and a >10% reduction in mPAP, the presence of intimal cellular thickening with an intimal area > 18% of vascular cross-sectional area, had an 85% predictive value for VN-PAH.⁶⁸

The distinct physiology of VR-PAH

A recent study has demonstrated the distinct physiology of VR-PAH versus VN-PAH, identifies the difference between “resistance” and “pressure” responders during an acute vasodilator challenge, and confirms that an isolated decrease in PVR in the absence of decreased PAP is not beneficial.^8,69 It also provides evidence that the VR-PAH lung can “normalize” perfusion with therapy, possibly explaining the excellent long-term prognosis for treated VR-PAH. Using a technique that measures first-pass transpulmonary metabolism (%M) and hydrolysis (v) of ³H-Benzoyl-Phe-Ala-Pro (BPAP) by the pulmonary capillary endothelium-bound angiotensin-converting ectoenzyme (ACE), the perfused functional capillary surface area (FCSA) can be determined and normalized to body surface area (FCSA/BSA).^70–74 The technique enables differentiating increased precapillary blood flow leading to microvascular recruitment, from increases in flow that simply distend already perfused vessels.^75,76 Twelve NR-PAH and two VR-PAH patients were studied, pre and at peak tolerated dose of intravenous epoprostenol (Fig. 7). The VR-PAH patients met the current criteria for vasoresponsiveness and were true “pressure” responders.⁵⁰ In the VN-PAH group, cardiac output increased by an average of 36%, with no change in mPAP, and an average decrease in PVR of 31%, typical of a “resistance” response. Determination of FCSA/BSA revealed reduced baseline levels in NR-PAH, indicative of an underperfused capillary bed with flow restricted by a remodeled upstream arteriolar bed. Moreover, despite increased cardiac output with the epoprostenol infusion, there was no recruitment of FCSA in the VN-PAH group, indicating persistent upstream pulmonary arteriolar luminal obstruction. Instead, the increased cardiac output was accommodated simply by distention of already perfused capillaries, with a shorter transit time, as evidenced by the decrease in %M and unchanged FCSA in many patients.⁷⁶ These findings provide a physiological basis for the “resistance” response and may explain the clinical failure of vasodilators that only provided a reduction in PVR without decreasing PAP.

Fig. 7.

Changes in mPAP, cardiac output, PVR, percent metabolism of ³H-BPAP, hydrolysis of BPAP (v), and determination of functional capillary surface area (FCSA) normalized to body surface area (BSA), before (Pre) and at peak (Peak) dose of an acute vasodilator challenge in patients with IPAH. The unfilled circles represent VN-PAH, the filled circles represent two patients with VR-PAH, and the filled gray square and triangle represent two VN-PAH patients with hemodynamic abnormalities of a similar severity to the patients with VR-PAH. Only the VR-PAH patients successfully recruit FCSA during the vasodilator challenge. Data are from Langleben et al.⁸

By contrast, the VR-PAH participants had a true “pressure” response, with decreased mPAP and increased cardiac output, resulting in decreased PVR. In those patents, FCSA/BSA was higher at baseline, but increased dramatically with epoprostenol. The rise in FCSA/BSA with little or no change in %M indicates that the increased cardiac output from rapid vasodilation of precapillary arterioles was accommodated via capillary recruitment, rather than distention.⁷⁶ The recruitment response seen in the VR-PAH patients is identical to that seen in normal humans performing exercise. It was noted previously that VR-PAH patients may have milder pulmonary hypertension at the time of evaluation.⁷ However, comparing the two VR-PAH with two VN-PAH that also had mild hemodynamic abnormalities, it is clear that the VN-PAH do not recruit microvasculature even when baseline hemodynamic abnormalities are mild (Fig. 7).

Given the rapid vasodilator response during an acute vasodilator challenge, these findings strongly suggest different microvascular abnormalities between VR-PAH and VN-PAH. Patients with VR-PAH must have principally and nearly exclusively a vasoconstrictive abnormality (Fig. 8). The acute vasoreactivity does not imply complete resolution of the vascular abnormality, only a reduction of the resistance to hemodynamically insignificant levels. By contrast, most VN-PAH patients must have severe cellular narrowing of arterioles, representing a physical obstruction to flow into underperfused capillary areas. Given that the distribution of histologic abnormalities is not uniform in IPAH, there may be some regions of the lung that can never see increased perfusion despite a higher driving cardiac output and the already, albeit abnormally, perfused regions must carry the flow via distention.

Fig. 8.

Schematic (not anatomic, nor positional) illustrations of pulmonary capillary perfusion in VR-PAH and VN-PAH. The ovals represent only a potential amount of capillary perfusion and do not represent acini. The blue vessels represent pulmonary arteries feeding into the capillaries. Pulmonary venous drainage is not shown. Left: VR-PAH, prior to vasodilation. Precapillary constriction increases PVR and reduces capillary perfusion diffusely; center: VR-PAH, during successful vasodilation. A marked increase in capillary perfusion occurs; right: VN-PAH. The precapillary arterioles have intraluminal cellular obstruction that greatly reduces or eliminates capillary perfusion. Any increased pulmonary blood flow during the acute vasodilator challenge is accommodated via distention of perfused capillaries, and not via recruitment.

The most encouraging finding in the study was the normalization of FCSA in the VR-PAH patients. This supports the long-term improvement in hemodynamics seen in those patients and the excellent prognosis. In support of this, a recent nuclear imaging study, using a radiolabeled adrenomedullin derivative, assessed pulmonary blood flow patterns in PAH patients.⁷⁷ It showed a completely normal perfusion pattern in one VR-PAH patient on calcium blockers, compared with persistently abnormal perfusion patterns in VN-PAH patients treated with approved PAH therapies (Fig. 9).

Fig. 9.

Radionuclide lung scans, using a molecule that binds to the endothelial adrenomedullin receptor, 99mTc-PulmoBind. Left: normal human; center: NR-PAH; right: VR-PAH on high dose calcium blocker therapy. Note the normal pattern of perfusion in VR-PAH as opposed to NR-PAH. Reproduced with permission from Harel et al.⁷⁷

Conclusion

There is now strong molecular, physiologic, and clinical evidence that true acute vasodilator responsive IPAH is a distinct clinical entity, with a specific therapy that provides long-term remissions. Efforts should be ongoing to provide a non-invasive method of diagnosing it and to provide a complete understanding of its pathogenesis. The fundamental problem may lie in abnormalities of cellular or mitochondrial calcium handling, in energetics of ion transport, or in other as yet unforeseen mechanisms. Further genome-wide studies should aid greatly and their chance of success will increase through multicenter collaborations that provide a larger cohort of carefully characterized VR-PAH patients. The progress in molecular characterization of VR-PAH, although incomplete, suggests that precision medicine is possible in PAH, offering the hope that it will lead to more effective therapy for VN-PAH. The fact that normal or near-normal microvascular perfusion can be attained with appropriate therapy in VR-PAH offers the hope that a similar objective can be reached in VN-PAH, when the precise therapies for that condition are found. Consideration should be given to assigning VR-PAH a distinct category within future classifications of group 1 pulmonary hypertension.

Footnotes

Conflict of interest

The author(s) declare that there is no conflict of interest.

Funding

This study was supported in part by the William and Ida Pencer Family Foundation, the Dimitrios Banousis Foundation, the Bank of Montreal Center for the Study of Heart Disease in Women, and the JGH Annual Walk for Pulmonary Hypertension, all at the Jewish General Hospital.

References

Stacher

Graham

Hunt

et al.

Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 186(3): 261–272.

Tuder

Archer

Dorfmuller

et al.

Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol 2013; 62(25 Suppl): D4–D12.

Hoeper

Bogaard

Condliffe

et al.

Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013; 62(25 Suppl): D42–D50.

Morrell

. Future breakthroughs in the genetics of pulmonary arterial hypertension. Pulm Circ 2013; 3(3): 451–453.

Rich

Brundage

. High dose calcium channel blocking therapy for primary pulmonary hypertension: evidence for long term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987; 76: 135–141.

Rich

Kaufmann

Levy

. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76–81.

Sitbon

Humbert

Jais

et al.

Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105–3111.

Langleben

Orfanos

Giovinazzo

et al.

Acute vasodilator responsiveness and microvascular recruitment in idiopathic pulmonary arterial hypertension. Ann Intern Med 2015; 162(2): 154–156.

Hemnes

Trammell

Archer

et al.

Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension. Circulation 2015; 131(4): 401–409.

10.

Hemnes

Zhao

West

et al.

Critical genomic networks and vasoreactive variants in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2016; 194(4): 464–475.

11.

Dresdale

Schultz

Michtom

. Primary pulmonary hypertension 1. Clinical and hemodynamic study. Am J Med 1951; 11: 686–705.

12.

Dresdale

Michtom

Schultz

. Recent studies in primary pulmonary hypertension including pharmacodynamic observations on pulmonary vascular resistance. Bull NY Acad Med 1954; 30: 195–207.

13.

Wood

. Pulmonary hypertension with special reference to the vasoconstrictive factor. Br Heart J 1958; 20(4): 557–570.

14.

Lupi-Herrera

Sandoval

Seoane

et al.

The role of hydralazine therapy for pulmonary arterial hypertension of unknown cause. Circulation 1982; 65(4): 645–650.

15.

Rubin

Peter

. Oral hydralazine therapy for primary pulmonary hypertension. N Engl J Med 1980; 302(2): 69–73.

16.

Ruskin

Hutter

Jr . Primary pulmonary hypertension treated with oral phentolamine. Ann Intern Med 1979; 90(5): 772–774.

17.

Kokubu

Kazatani

Hamada

et al.

Is captopril effective in primary pulmonary hypertension?

Jpn Circ J 1982; 46(10): 1095–1097.

18.

Wang

Pohl

Rowlands

et al.

Diazoxide in treatment of primary pulmonary hypertension. Br Heart J 1978; 40(5): 572–574.

19.

Klinke

Gilbert

. Diazoxide in primary pulmonary hypertension. N Engl J Med 1980; 302(2): 91–92.

20.

Hall

Petch

. Reversibility of primary pulmonary hypertension during six years of treatment with oral diazoxide. Br Heart J 1987; 58(4): 420.

21.

Daoud

Reeves

Kelly

. Isoproterenol as a potential pulmonary vasodilator in primary pulmonary hypertension. Am J Cardiol 1978; 42(5): 817–822.

22.

Camerini

Alberti

Klugmann

et al.

Primary pulmonary hypertension: effects of nifedipine. Br Heart J 1980; 44(3): 352–356.

23.

Samet

Bernstein

Widrich

. Intracardiac infusion of acetylcholine in primary pulmonary hypertension. Am Heart J 1960; 60: 433–439.

24.

Charms

. Primary pulmonary hypertension. Effect of unilateral pulmonary artery occlusion and infusion of acetylcholine. Am J Cardiol 1961; 8: 94–99.

25.

. Primary pulmonary hypertension: report of six cases and review of literature. Ann Intern Med 1958; 49(5): 1138–1161.

26.

Gardner

. The effect of priscol in pulmonary hypertension. Australas Ann Med 1954; 3(1): 59–63.

27.

Packer

Greenberg

Massie

et al.

Deleterious effects of hydralazine in patients with pulmonary hypertension. N Engl J Med 1982; 306(22): 1326–1331.

28.

Kronzon

Cohen

Winer

. Adverse effect of hydralazine in patients with primary pulmonary hypertension. JAMA 1982; 247(22): 3112–3114.

29.

Cohen

Kronzon

. Adverse hemodynamic effects of phentolamine in primary pulmonary hypertension. Ann Intern Med 1981; 95(5): 591–592.

30.

Rich

Martinez

Lam

et al.

Captopril as treatment for patients with pulmonary hypertension. Problem of variability in assessing chronic drug treatment. Br Heart J 1982; 48(3): 272–277.

31.

Leier

Bambach

Nelson

et al.

Captopril in primary pulmonary hypertension. Circulation 1983; 67(1): 155–161.

32.

Buch

Wennevold

. Hazards of diazoxide in pulmonary hypertension. Br Heart J 1981; 46(4): 401–403.

33.

Rubino

Schroeder

. Diazoxide in treatment of primary pulmonary hypertension. Br Heart J 1979; 42(3): 362–363.

34.

Honey

Cotter

Davies

et al.

Clinical and haemodynamic effects of diazoxide in primary pulmonary hypertension. Thorax 1980; 35(4): 269–276.

35.

Elkayam

Frishman

Yoran

et al.

Unfavorable hemodynamic and clinical effects of isoproterenol therapy in primary pulmonary hypertension. Cardiovasc Med 1978; 3: 1177.

36.

Berkenboom

Sobolski

Stoupel

. Failure of nifedipine treatment in primary pulmonary hypertension. Br Heart J 1982; 47(5): 511.

37.

Reeves

Groves

Turkevich

. The case for treatment of selected patients with primary pulmonary hypertension. Am Rev Respir Dis 1986; 134(2): 342–346.

38.

Rich

Martinez

Lam

et al.

Reassessment of the effects of vasodilator drugs in primary pulmonary hypertension: guidelines for determining a pulmonary vasodilator response. Am Heart J 1983; 105(1): 119–127.

39.

Sitbon

Brenot

Denjean

et al.

Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995; 151(2 Pt 1): 384–389.

40.

Opitz

Wensel

Bettmann

et al.

Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J 2003; 24(4): 356–365.

41.

Rubin

Groves

Reeves

et al.

Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 1982; 66(2): 334–338.

42.

Hoeper

Olschewski

Ghofrani

et al.

A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol 2000; 35(1): 176–182.

43.

Voswinckel

Enke

Reichenberger

et al.

Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol 2006; 48(8): 1672–1681.

44.

Galie

Ussia

Passarelli

et al.

Role of pharmacologic tests in the treatment of primary pulmonary hypertension. Am J Cardiol 1995; 75(3): 55A–62A.

45.

Sitbon

Humbert

Jagot

et al.

Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998; 12(2): 265–270.

46.

Morgan

McCormack

Griffiths

et al.

Adenosine as a vasodilator in primary pulmonary hypertension. Circulation 1991; 84(3): 1145–1149.

47.

Nootens

Schrader

Kaufmann

et al.

Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. Chest 1995; 107(1): 54–57.

48.

Pepke-Zaba

Higenbottam

Dinh-Xuan

et al.

Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991; 338(8776): 1173–1174.

49.

Palevsky

Long

Crow

et al.

Prostacyclin and acetylcholine as screening agents for acute pulmonary vasodilator responsiveness in primary pulmonary hypertension. Circulation 1990; 82(6): 2018–2026.

50.

Galie

Humbert

Vachiery

et al.

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46(4): 903–975.

51.

Rich

Kaufmann

. High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for short-term drug testing. J Am Coll Cardiol 1991; 18(5): 1323–1327.

52.

Montani

Savale

Natali

et al.

Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J 2010; 31(15): 1898–1907.

53.

de Jesus Perez

Alastalo

et al.

Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt-beta-catenin and Wnt-RhoA-Rac1 pathways. J Cell Biol 2009; 184(1): 83–99.

54.

Chow

Fessel

Kaoriihida

et al.

Dysfunctional resident lung mesenchymal stem cells contribute to pulmonary microvascular remodeling. Pulm Circ 2013; 3(1): 31–49.

55.

West

Austin

Gaskill

et al.

Identification of a common Wnt-associated genetic signature across multiple cell types in pulmonary arterial hypertension. Am J Physiol Cell Physiol 2014; 307(5): C415–C430.

56.

Awad

Dalal

Cho

et al.

DSG2 mutations contribute to arrhythmogenic right ventricular dysplasia/cardiomyopathy. Am J Hum Genet 2006; 79(1): 136–142.

57.

Pilichou

Nava

Basso

et al.

Mutations in desmoglein-2 gene are associated with arrhythmogenic right ventricular cardiomyopathy. Circulation 2006; 113(9): 1171–1179.

58.

Garcia-Gras

Lombardi

Giocondo

et al.

Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. J Clin Invest 2006; 116(7): 2012–2021.

59.

Corrado

Link

Calkins

. Arrhythmogenic right ventricular cardiomyopathy. N Engl J Med 2017; 376(1): 61–72.

60.

van Opbergen

Delmar

van Veen

. Potential new mechanisms of pro-arrhythmia in arrhythmogenic cardiomyopathy: focus on calcium sensitive pathways. Neth Heart J 2017; 25(3): 157–169.

61.

Chunqiu

Pessin

. Lipid Raft targeting of the TC10 amino terminal domain is responsible for disruption of adipocyte cortical actin. Mol Biol Cell 2003; 14(9): 3578–3591.

62.

Kanzaki

. Insulin receptor signals regulating GLUT4 translocation and actin dynamics. Endocr J 2006; 53(3): 267–293.

63.

Pugh

Robbins

Rice

et al.

Unrecognized glucose intolerance is common in pulmonary arterial hypertension. J Heart Lung Transplant 2011; 30(8): 904–911.

64.

West

Niswender

Johnson

et al.

A potential role for insulin resistance in experimental pulmonary hypertension. Eur Respir J 2013; 41(4): 861–871.

65.

Renard

Paulin

Breuils-Bonnet

et al.

Pim-1: A new biomarker in pulmonary arterial hypertension. Pulm Circ 2013; 3(1): 74–81.

66.

Paulin

Courboulin

Meloche

et al.

Signal transducers and activators of transcription-3/pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension. Circulation 2011; 123(11): 1205–1215.

67.

Satyanarayana Rao

Moller

Edwards

. Primary pulmonary hypertension in a child. Response to pharmacologic agents. Circulation 1969; 40(4): 583–587.

68.

Palevsky

Schloo

Pietra

et al.

Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents. Circulation 1989; 80(5): 1207–1221.

69.

Brittain

Hemnes

. Vasodilator-responsive idiopathic pulmonary arterial hypertension: evidence for a new disease? Ann Intern Med 2015; 162(2): 148–149.

70.

Orfanos

Langleben

Khoury

et al.

Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in humans. Circulation 1999; 99: 1593–1599.

71.

Orfanos

Armaganidis

Glynos

et al.

Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in acute lung injury. Circulation 2000; 102: 2011–2018.

72.

Orfanos

Psevdi

Stratigis

et al.

Pulmonary capillary endothelial dysfunction in early systemic sclerosis. Arthritis Rheum 2001; 44(4): 902–911.

73.

Langleben

Orfanos

Giovinazzo

et al.

Pulmonary capillary endothelial metabolic dysfunction: severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertension. Arthritis Rheum 2008; 58(4): 1156–1164.

74.

Orfanos

Hirsch

Giovinazzo

et al.

Pulmonary capillary endothelial metabolic function in chronic thromboembolic pulmonary hypertension. J Thromb Haemost 2008; 6(8): 1275–1280.

75.

Toivonen

Catravas

. Effects of blood flow on lung ACE kinetics: evidence for microvascular recruitment. J Appl Physiol 1991; 71(6): 2244–2254.

76.

Orfanos

Ehrhart

Barman

et al.

Endothelial ectoenzyme assays estimate perfused capillary surface area in the dog lung. Microvasc Res 1997; 54: 145–155.

77.

Harel

Langleben

Provencher

et al.

Molecular imaging of the human pulmonary vascular endothelium in pulmonary hypertension: a phase II safety and proof of principle trial. Eur J Nucl Med Mol Imaging 2017; 44(7): 1136–1144.